Mizuho Said Adaptimmune Therapeutics plc (ADAP) ASCO Data 'Incrementally Supportive'

Mizuho Securities analyst Mara Goldstein reiterated a Neutral rating and $3.00 price target on Adaptimmune Therapeutics plc (NASDAQ: ADAP), but said ASCO data was "incrementally supportive, acceleration of Synovial Sarcoma trial."

The analyst commented, "ADAP reported a substantial data update this morning via press release and a companion video (LINK), ahead of presentation/discussion of its ASCO presentation. The data show continued activity in the SPEARHEAD-1/ADP-A2M4 program (facilitating a shortened clinical program) and new data updates in the SURPASS program, suggesting the potential for broader utilization of ADAP's SPEAR-T cells. We see this data update as positive and supportive, though the numbers are still modest and early, which tempers our view."

For an analyst ratings summary and ratings history on Adaptimmune Therapeutics plc click here. For more ratings news on Adaptimmune Therapeutics plc click here.

Shares of Adaptimmune Therapeutics plc closed at $4.86 yesterday.

You May Also Be Interested In

• Berenberg Downgrades QIAGEN NV (QIA:GR) (QGEN) to Hold
• JPMorgan Starts Lotte Shopping Co Ltd (023530:KS) at Neutral
• Goldman Sachs Downgrades EssilorLuxottica SA (EL:FP) (ESLOY) to Neutral